JCR Pharmaceuticals Co., Ltd.
4552.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥33,072 | ¥42,871 | ¥34,343 | ¥51,082 |
| % Growth | -22.9% | 24.8% | -32.8% | – |
| Cost of Goods Sold | ¥11,524 | ¥11,620 | ¥8,886 | ¥10,461 |
| Gross Profit | ¥21,548 | ¥31,251 | ¥25,457 | ¥40,621 |
| % Margin | 65.2% | 72.9% | 74.1% | 79.5% |
| R&D Expenses | ¥15,431 | ¥11,234 | ¥8,802 | ¥7,175 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥12,958 | ¥12,486 | ¥11,678 | ¥13,511 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥28,389 | ¥23,720 | ¥20,480 | ¥20,686 |
| Operating Income | -¥6,841 | ¥7,532 | ¥4,975 | ¥19,933 |
| % Margin | -20.7% | 17.6% | 14.5% | 39% |
| Other Income/Exp. Net | ¥236 | -¥288 | ¥437 | -¥529 |
| Pre-Tax Income | -¥6,414 | ¥7,244 | ¥5,412 | ¥19,404 |
| Tax Expense | -¥1,718 | ¥1,707 | ¥1,625 | ¥4,886 |
| Net Income | -¥4,758 | ¥5,507 | ¥3,772 | ¥14,507 |
| % Margin | -14.4% | 12.8% | 11% | 28.4% |
| EPS | -38.43 | 44.13 | 30.34 | 117.26 |
| % Growth | -187.1% | 45.5% | -74.1% | – |
| EPS Diluted | -38.43 | 43.92 | 30.22 | 116.79 |
| Weighted Avg Shares Out | 124 | 125 | 124 | 124 |
| Weighted Avg Shares Out Dil | 124 | 125 | 125 | 124 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥113 | ¥111 | ¥33 | ¥7 |
| Interest Expense | ¥155 | ¥86 | ¥44 | ¥45 |
| Depreciation & Amortization | ¥3,374 | ¥3,197 | ¥1,997 | ¥1,945 |
| EBITDA | -¥2,885 | ¥10,528 | ¥7,453 | ¥21,394 |
| % Margin | -8.7% | 24.6% | 21.7% | 41.9% |